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To:  Dr E.E. Moore 
 Editor, Journal of Trauma and Acute Care Surgery. 
 
Thank you for the opportunity to re-revise our manuscript and respond to the reviewer’s 
comments. We acknowledge the valid concerns that have been raised, and have taken further 
steps to clarify our analysis strategy, provide additional information regarding the groups, 
and address the potential confounders relating to our observations. We have highlighted all 
changes in the manuscript text, and we include a point-by-point response to each of the 











Response to Reviewer: 
 
I must echo the previous reviewer 2's comments about the confusing description of the 
groups. I acknowledge the efforts of the authors to improve this description but a diagram (as 
recommended by the reviewer) would do wonders to improve the clarity of the grouping. 
 
We have included a flow diagram (figure 1) illustrating the inclusion and exclusion 
strategy, and have attempted to make the grouping clearer in the text. 
 
I am also concerned (also echoing previous comments) that there are multiple confounders 
that can explain the findings, for which some form of adjustment is very much needed. I was 
unable to understand the authors' stated efforts to deal with the confounders (in which case 
the readers are likely to not understand as well). Assuming there are enough patients, survival 
analysis with time-varying covariates is a possibility using a propensity score (not for 
matching but as an adjustor for the confounders. A more elegant approach to the comparisons 
would be to model the interaction with platelet transfusion, but this is not a deal breaker. 
Also, comparing patients over time using a repeated measures approach would be useful and 
very elegant. 
 
Thank you for these comments. We accept that there are confounders which could 
potentially contribute to our observations. Our analysis compares patients at a series of 
sampling points during resuscitation. Regarding our observations on trends in platelet 
aggregation, we have now included a table (table 2) outlining the characteristics of the 
groups being compared at each point. This demonstrates that there are no significant 
differences in injury characteristics or outcomes between the groups being compared, 
which we hope will mitigate some of the reviewer’s concerns. The variation in time of 
sampling has been described in the results section and acknowledged in the limitations. 
 
For the comparison of plasma proteins and viscoelastic measures, we have compared 
intervals rather than patients, and thus matching based on injury characteristics is not 
possible. This approach enabled us to adjust for concomitant FFP administration, a 
major confounder when considering interval changes in viscoelastic and plasma protein 
measurements. We have also conducted additional analyses regarding the relative 
duration of intervals, which show that this does not appear to represent a major 
confounder within our dataset. This is described in the results section and discussed in 
the limitations. Unfortunately, there are insufficient patient numbers for a propensity-
score based approach. 
 
The statistical tests described in Methods are inconsistent with the methods in Figures 
(possibly just the name, but possibly the tests are different?). Please provide consistent 
information for the statistical tests. 
 
Thank you. We have corrected this omission in the text. 
 
Minor: please replace the term parameter by variable or similar. Please include the study 
period in the Abstract. "Data" are not parametric/not parametric, "distributions" are. 
 





Platelets play a critical role in hemostasis with aberrant function implicated in trauma-
induced coagulopathy. However, the impact of massive transfusion protocols on platelet 
function during trauma hemorrhage is unknown. The aim of this study was to characterize the 
effects of platelet transfusion on platelet aggregation and fibrinolytic markers during 
hemostatic resuscitation.  
Methods 
Trauma patients enrolled into the prospective Activation of Coagulation and Inflammation in 
Trauma (ACIT) study between January 2008 and November 2015 who received at least four 
units of packed red blood cells (PRBCs) were included. Blood was drawn in the emergency 
department within 2 hours of injury and at intervals after every 4 units of PRBCs transfused. 
Platelet aggregation was assessed in whole blood with multiple electrode aggregometry. 
Plasma proteins were quantified by enzyme-linked immunosorbent assay.  
Results 
Of 161 patients who received 4 or more PRBCs as part of their initial resuscitation, 44 
received 8-11 units and 28 received 12 units or more. At each time point during bleeding, 
platelet aggregation was similar in patients who had received a platelet transfusion compared 
to those who had only received other blood products (p>0.05 for all time points). Platelet 
transfusion during the 4PRBC intervals was associated with a decrease in maximum lysis on 
rotational thromboelastometry (start of interval 6% [2-12] vs end of interval 2% [0-5], 
p=0.001), an increase in plasminogen activator inhibitor-1 (PAI-1; start of interval: 35.9 +/- 
Abstract
14.9 vs end of interval: 66.7 +/- 22.0, p=0.007) and a decrease in tissue plasminogen activator 
(start of interval: 26.2 +/- 10.5 vs end of interval: 19.0 +/- 5.1, p=0.04). No statistically 
significant changes in these parameters occurred in intervals which did not contain platelets.  
Conclusion 
Current hemostatic resuscitation strategies do not appear to restore platelet aggregation 
during active hemorrhage. However, stored platelets may attenuate fibrinolysis by providing 
an additional source of PAI-1. Further investigation into the effects of early platelet 
transfusion on platelet function, haemostatic and clinical outcomes during bleeding are 
warranted.  
 
Level of Evidence: Prospective observational study, level III 
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Hemorrhage is the principal cause of preventable death due to injury.1 Contemporary 
damage-control resuscitation (DCR) is characterised by expedited hemorrhage control with 
simultaneous and empiric transfusion of blood and blood products in high ratios.2  
Maintaining hemostatic potential through early administration of plasma and platelets in high 
volumes alongside transfusion of packed red blood cells (PRBCs) minimises dilutional 
coagulopathy and is associated with improved outcomes.3  However, the effects of platelet 
transfusions remain unclear, while the provision of platelet transfusions can be challenging.  
Platelet function is known to be reduced in Trauma-Induced Coagulopathy (TIC),4,5 but the 
effects of platelet transfusion on coagulation during active bleeding are unknown. This 
knowledge gap has been highlighted by several contemporary major hemorrhage 
guidelines.6,7  
 
Platelets promote coagulation primarily by adhering to the endothelium or subendothelium to 
form aggregates at sites of vascular injury, and by providing a phospholipid platform to 
support thrombin generation.8 Haemostasis is further amplified through the release of 
reactive mediators from platelet storage granules into the plasma space,9 including clotting 
factors and mediators of fibrinolysis. In particular, platelets contain a large pool of 
plasminogen activator inhibitor-1 (PAI-1)10 and alpha -2 antiplasmin (A2AP),11 which are 
hypothesised to represent an important mechanism through which platelets attenuate tissue 
plasminogen activator (tPA)-mediated fibrinolysis in vitro.12,13 Impaired platelet aggregation 
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is common after severe injury and associated with increased mortality, although the 
mechanisms of this remain unknown.14-16 Attempts to support platelet function through 
transfusion of allogeneic platelets during major haemorrhage therefore seems logical, but to 
date no studies have evaluated how platelet transfusions affect hemostasis during bleeding in 
trauma patients. 
 
Our working hypothesis was that platelet transfusions exert their effects either through 
augmenting aggregation, promoting thrombin generation or by the release of granule contents 
into the plasma space. In this study, our objectives were to describe changes in whole blood 
platelet aggregation, rotational thromboelastometry, circulating levels of platelet-derived 
clotting factors, and plasma markers of fibrinolysis resulting from platelet transfusion. We 
compared interval changes in bleeding trauma patients receiving blood component therapy 




Study design and participants 
Patients recruited into the ACIT II (UK CRN ID 5637) prospective, observational study at an 
urban major trauma centre in the United Kingdom between January 2008 and November 
2015 were eligible for inclusion. Entry and exclusion criteria for ACIT II have been 
published in detail previously.17 The study was approved by the local Research Ethics 
Committee (reference 07/Q0603/29). For this study patients who received less than 4 units of 
packed red blood cells (PRBCs) were retrospectively excluded, to focus on bleeding patients 
who received platelet transfusions and to allow longitudinal analyses during bleeding. Assent 
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for patient recruitment was initially provided by an independent physician, with written 
informed consent obtained from a patient or relative as soon as possible after enrollment. 
 
Major Hemorrhage Protocol 
At our institution, activation criteria for the MHP are a systolic blood pressure <90mmHg, 
poor response to initial fluid resuscitation and/or clinical suspicion of active hemorrhage.  
MHP activation occurs either from scene by the physician-led prehospital care team or upon 
arrival in the Emergency Department (ED) by the trauma team leader. Empiric transfusion 
with a FFP:Platelet:PRBC target ratio of 1:1:1 is initiated with ‘pack A’, which contains 4 
units of PRBCs and 4 units of FFP. Universal donor PRBCs and thawed FFP are available in 
ED for immediate transfusion. If bleeding continues, ‘pack B’ and all subsequent packs 
provide 6 PRBC, 6 FFP, 2 pools of cryoprecipitate and 1 apheresis unit of platelets; the order 
of administration of these products is at the discretion of the clinical team. The MHP was 
updated to include tranexamic acid (TXA) administration in February 2011 and pre-hospital 
transfusion of up to four units of PRBCs in January 2014.  
 
Blood sampling  
Blood was drawn for research purposes within 20 minutes of arrival in ED from either the 
femoral vein or antecubital fossa, alongside routine laboratory tests. Blood product use prior 
to this initial sample draw was recorded. Platelet counts were measured with a Coulter 
LH750 hematology analyzer (Beckman Coulter, CA, USA; normal range 150-400x109/L). 
Point-of-care arterial blood gas analysis was performed to determine base deficit (BD) and 
lactate concentration. In patients who received transfusion of blood products, further samples 
were obtained after every 4th unit of PRBC, up to and including the 12th unit. Samples were 
processed by a member of the research team within 45 minutes of collection.  
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Platelet Aggregation and Thromboelastometry 
Platelet aggregation was assayed in whole blood with multiple electrode impedance 
aggregometry using the Multiplate analyzer (Roche pharmaceuticals, Sussex, UK). 
Samples were processed according to the manufacturer’s instructions. Briefly, blood was 
collected into a 3ml vacutainer (Roche pharmaceuticals) containing >15g/ml hirudin. 
Aggregation was measured in 300l of blood over six minutes in response to 6.5M 
adenosine diphosphate (ADP), 0.5mM Arachidonic acid (AA), 3.2g/ml collagen and 32M 
thrombin-receptor activating peptide-6 (TRAP; final concentrations given). Results are 
reported as area under the curve (AUC) in arbitrary units. Hypo- and hyperfunction were 
defined according to references ranges stated by the manufacturer (570-1130U for ADP, 710-
1150U for AA, 720-1250U for collagen and 840-1280U for TRAP). Rotational 
thromboelastometry (ROTEM) was performed on citrated whole blood using a ROTEM 
delta instrument in the presence of tissue factor (EXTEM) and with the addition of 
cytochalasin D, an inhibitor of platelet aggregation (FIBTEM).  
 
Clotting Factors and Fibrinolytic markers 
For quantification of plasma coagulation protein levels, blood was drawn into 4.5ml glass 
vacutainer containing 3.2% sodium citrate (Becton, Dickinson and Company, Plymouth, UK) 
and centrifuged at 1,750g for ten minutes. The plasma component was then removed and re-
centrifuged at the same speed and duration prior to storage at -80C. Immediately after 
thawing levels of factor II (reference range 70-146iu/dL), factor V (66-114iu/dL), factor XIII 
(55-158iu/dL), D-dimer (0-440ng/mL), von Willebrand antigen (50-160iu/dL), soluble fibrin 
monomer complex (0-6g/mL) and alpha-2 antiplasmin (A2AP; 68-136iu/dL) were 
quantified in the hospital laboratory with a Sysmex CS2100i automated analyzer (Sysmex, 
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UK) according to standard protocols; results are reported in international units. Levels of 
PAI-1 (4-43ng/mL), tPA (2-12ng/mL), plasmin-antiplasmin complex (PAP; 120-700g/L) 
and prothrombin fragments 1+2 (PF1+2; 69-229pmol/L) were measured using sandwich 
enzyme-linked immunosorbent assay (ELISA; Asserchrom®, Diagnostica Stago). 
 
Data Collection  
Demographic data, injury characteristics and physiological variables were collected 
prospectively. Cessation of blood product transfusion was used as a surrogate of hemostasis 
for the purposes of this study. Daily follow-up was performed for the first 28 days of hospital 
stay or until death or discharge.  Multiple Organ Dysfunction Syndrome (MODS) was 




Data were analysed separately to assess the effect of platelet transfusion on platelet 
aggregation, with a subgroup analysis to examine the changes in coagulation factors and 
ROTEM.  First, to study the impact of platelet transfusion on platelet aggregation over time 
during resuscitation, patients were divided into two groups at each sampling point (4 unit 
PRBC, 8 unit PRBC, 12 unit PRBC): (1) those that received a platelet transfusion and (2) 
those that did not receive a platelet transfusion prior to each sampling point. To mitigate the 
potential effects of selection bias, we divided patients into those who received a massive 
transfusion (MT, defined as ≥ 10 PRBC units in 24 hours) and patients who required less than 
10 PRBC units. Second, we divided all available 4 unit PRBC intervals into three groups 
depending on the blood products administered during this interval: PRBCs only; PRBCs and 
FFP; or PRBCs, FFP and platelets. This approach was taken to isolate the effects of 
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platelet transfusion on plasma protein levels and viscoelastic measurements from those 
of FFP. Interval changes were calculated by subtracting the value at the end of the interval 
from the value at the beginning of the interval.  
 
Data analysis was performed using Excel v15.2 (Microsoft, CA) and Prism v6.0 (GraphPad 
software, CA). Normal-quantile plots were used to assess the distribution of continuous data. 
Data from non-parametric distributions are reported as median with interquartile range 
(IQR) and were compared with the Mann-Whitney U-test, Kruskall-Wallis test with Dunn’s 
post-test, or Wilcoxon matched pairs test. Data from parametric distributions are 
presented as mean +/- 95% confidence intervals and were compared with Student’s or paired 
T-test as applicable, or one-way analysis of variance (ANOVA) with Tukey’s post-hoc test 
for multiple comparisons. Correlation was assessed with Spearman’s coefficient. 
Categorical data are displayed as number and percentage and were compared with Fisher’s 




One-hundred sixty-one patients received at least 4 PRBCs and were included in the study 
(figure 1). Eighty-two patients received PRBC transfusion prior to baseline sampling, median 
1 PRBC units (0-2).  Patients who received platelets (n=107) during the first 24 hours had 
similar injury severity to those who did not receive a platelet transfusion (n=54) but were 
significantly more shocked, with longer length of hospital stay and increased rates of organ 
failure (Table 1).  A non-significant trend towards reduced mortality at 24 hours in 
patients receiving platelets was observed (platelets transfused: 8/107 (7%) vs no 
platelets transfused 9/54 (17%), p=0.10). Median time from admission to platelet 
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transfusion was 90 (63-166) minutes and patients who required a platelet transfusion received 
significantly more blood and blood products (FFP, cryoprecipitate) during the first 24 hours 
(Table 1).  The average ratio of platelets to PRBCs, assuming one apheresis unit to be 
equivalent to 6 units of PRBCs, was 0.3 between 0-4 PRBCs, 0.9 between 5-8 PRBCs and 
1.2 between 9-12 PRBCs. 
 
On admission to ED, more than one in four patients who required over 4 PRBC units had 
evidence of reduced platelet aggregation in response to agonist stimulation: ADP: 70 (42%), 
AA: 59 (36%), collagen: 38 (24%), TRAP: 38 (24%). Patients who received ≥10PRBCs, 
(n=42) had lower platelet aggregation at admission compared to patients who received 4-9 
PRBC units: ADP, MT 477 (158-790) vs no MT 681 (331-1007), p=0.016; AA, MT 635 
(411-893) vs no MT 891 (591-1242), p=0.001; collagen, MT 747 (4678-993) vs no MT 940 
(559-1262), p=0.033; TRAP, MT 1032 (650-1171) vs no MT 1277 (903-1584), p=0.006. 
Seventy-one patients had at least one additional sample taken for aggregometry during 
bleeding, after an average of 57 minutes (4 PRBC interval), 87 minutes (8 PRBC interval) 
and 130 minutes (12 PRBC interval) from admission. Compared to patients who only 
underwent baseline sampling, these patients had a similar severity of injury (30 (22-38) 
vs (29 (18-40), p=0.10), depth of shock (8.9 (6.0-16.9) vs 7.4 (3.9-13mmol/L), p=0.13), 
and overall mortality (20/71 (28%) vs 23/90 (26%), p=0.72) 
 
In patients who received a massive transfusion and had samples during hemorrhage, platelet 
aggregation declined significantly during resuscitation (figure 2A-D) compared with 
admission. A similar pattern in aggregation was observed in patients who received more than 
four PRBC units but did not require a massive transfusion (supplemental figure 1A-D). 
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Comparing patients who had received platelets with those who had not received platelets 
prior to each sampling point, levels of platelet aggregation were similar (p>0.05 at each 
sample time-point). At each sampling point, groups were comparable in terms of injury 
severity and depth of shock, although patients who received platelets tended to have 
samples taken later after admission (table 2). Aggregation in response to each of the 
agonists deteriorated at each sampling point during bleeding compared to baseline, and on 
average by 8 PRBC units had decreased from the admission value by 81% in patients who 
did not receive platelets and 78% in patients who had a platelet transfusion. Platelet count 
also declined during haemorrhage irrespective of platelet transfusion. After 8 PRBC units, the 
platelet count in those who received platelets was 97 (71-106) x109/L versus 109 (79-137) 
x109/L (p=0.81) in those who did not receive a platelet transfusion by this sample point.  
 
We next assessed the efficacy of platelet transfusion on ROTEM variables in a subset of 
patients who had plasma coagulation protein levels measured during bleeding at each 4 unit 
PRBC interval (n=89).  Overall, 115 interval samples were available for analysis - FFP was 
administered in 85 intervals of which 29 included at least one pool of platelets (Table 2).  
Compared to the main study cohort, this subgroup were more severely injured (ISS 34 [25-
42] vs 29 [20-38], p=0.03) but had a similar degree of shock (BD 8.9 +/- 1.3mmol/L vs 9.8 
+/- 1.1mmol/L, p=0.31), PRBC transfusion (8 [6-11] units vs 7 [5-10] units, p=0.09) and 28-
day mortality (29 [33%] vs 40 [28%], p=0.24). The proportion of patients who received TXA 
prior to or during the interval was similar when PRBCs were given alone (33%), with FFP 
(38%) or with FFP and platelets (50%; p=0.39, chi-squared test). Intervals which contained 
platelets and FFP were longer in duration compared to those containing FFP without 
platelets (84 (44-147) vs 46 (30-85) minutes, p=0.05).  
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Comparing intervals in which platelets were transfused with those in which only FFP and 
PRBC were administered, there was no significant difference in viscoelastic measurement of 
clotting time, clot formation or clot strength (table 3).  However, platelet transfusion was 
associated with a significant reduction in EXTEM maximum lysis (ML) (Figure 3A).  
Changes in circulating clotting factor levels were similar, irrespective of whether or not 
platelet transfusions were administered during a 4 unit PRBC interval (Table 3). Platelet 
transfusion during an interval was associated with a significant increase in circulating levels 
of PAI-1 compared to intervals in which PRBCs and FFP were administered (Figure 3B). 
Conversely, levels of soluble tPA decreased in intervals where platelets were transfused in 
combination with PRBCs and FFP (Figure 3C). PAP complex levels declined in intervals 
containing PRBCs and FFP regardless of whether platelets were transfused (Figure 3D). No 
correlation was observed between interval duration and change in EXTEM ML (r=0.13, 
p=0.27), PAI-1 (r=0.17, p= 0.19) or tPA (r=-0.07, p=0.63). Overall, the only clear effects of 
platelet transfusions appeared to be a reduction in fibrinolysis with minimal effect on other 




In this prospective single-centre cohort study, the strongest effect of platelet transfusion 
during trauma hemorrhage appears to be reduction of fibrinolysis without improvement in 
clot strength or clotting times.  Administering platelets as part of a major haemorrhage 
protocol did not restore platelet aggregation or platelet count. Compared to transfusion of 
FFP and PRBC alone, platelets transfusions improved viscoelastic measures of fibrinolysis 
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with increased plasma PAI-1 levels and reduced circulating tPA. In cohort studies, high 
platelet:PRBC ratios appear to be associated with improved outcomes.18-20 The reduction in 
early deaths due to exsanguination in the 1:1:1 arm of the PROPPR randomized control trial 
may due to the effects of early platelet administration rather than (or as well as) the higher 
doses of blood components. Reduction of hyperfibrinolysis] may be a key mechanism by 
which early platelet transfusion improves hemostasis in TIC.  
 
Platelets contain a broad array of pro- and anti-coagulant factors which are released into the 
plasma space upon activation.9 Of particular relevance to the potential role of platelets in 
Acute Traumatic Coagulopathy (ATC) and TIC are inhibitors of fibrinolysis including PAI-1. 
Although the activity of platelet-derived PAI-1 has been questioned,21 recent evidence 
suggests that the active form is stored in large quantities within platelet alpha granules.10 In 
ATC, activated protein C-dependent fibrinolysis is thought to occur through inhibition of 
PAI-1, which allows tPA mediated plasminogen cleavage to proceed unchecked.22-24 Our 
findings suggest that transfusion of stored platelets may provide an important source of PAI-
1, which forms an inactive complex with circulating tPA and hypothetically reduces the level 
of free tPA detectable in plasma.25 FFP contains antiplasmin although platelet transfusion had 
an additive effect on reversal of functional fibrinolysis as demonstrated by a reduced 
maximum lysis. Although changes in PAP and D-dimer levels were not significantly different 
after platelet transfusions, this may be attributable to the long half-life of these biomarkers in 
the circulation. Both assays describe prior fibrinolytic activation rather than the dynamic 
changes in fibrinolysis during bleeding.26 This apparent predominant effect of platelet 
transfusion is supported by in vitro evidence that platelet lysate attenuates tPA-dependent 
fibrinolysis12 and raises the question of whether earlier administration of platelets could 
confer additional benefit particularly in patients with hyperfibrinolysis. 
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Trauma-induced platelet dysfunction on arrival to ED has been previously described by 
several authors,14-16 and it is plausible that the conditions which impair the function of 
endogenous platelets may have the same effect on stored platelets administered in 
transfusion. Whether trauma-induced platelet dysfunction is an intrinsic platelet defect or the 
result of circulating conditions is unknown and requires further study. With regards to 
platelet count, it is possible that the rate of platelet loss through ongoing bleeding exceeded 
the number of platelets being administered in our patient cohort. Alternatively, stored 
platelets may form microaggregates or be recruited to thrombus formation, and thus escape 
detection by the laboratory platelet count.27 These hypotheses remain speculative however, 
and further investigation is required to determine how the post-injury intravascular milieu 
impacts upon the function of both stored and endogenous platelets. 
 
There are a number of limitations to this study, principally as a result of its observational 
design. First, comparisons of interval changes in clotting factor levels and viscoelastic tests 
could in theory be influenced by variations in the rate of blood loss and the time of 
sampling, which was slightly later after admission in patients receiving platelets. 
Second, given the sample sizes for each interval we were unable to fully control for 
concomitant administration of FFP and cryoprecipitate. Third, we were not able to evaluate 
the effect of timing of platelet transfusion as part of our MHP. In particular, whether ‘up 
front’ platelet transfusion, as administered in the 1:1:1 arm of the PROPPR trial, conferred 
additional hemostatic benefits could not be addressed in this study due to the design of the 
MHP at out institution.  Platelets are delivered in the second MHP pack and therefore later in 
the clinical episode. Further work is required to assess other possible sources for the delayed 
rise in PAI-1 e.g. reperfusion injury of hypoperfused endothelium.  Fourth, we did not 
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directly measure thrombin generation potential but used PF 1+2 fragments in plasma as a 
surrogate.  Platelet transfusion has been advocated as a method to support thrombin 
generation28 although we found no significant difference in PF 1+2 fragments between 
groups. Fifth, we did not perform any functional coagulation tests on the apheresis platelet 
units themselves as this forms part of an ongoing study. Finally, we did not undertake a 
detailed evaluation of the impact of platelet transfusion on clinical outcomes although these 
have previously been described in larger multi-centre studies.3,18 Our novel findings 
demonstrating a potential role for platelets in reducing fibrinolytic activity as measured by 
laboratory assays, and requires clinical validation in larger trauma trials.  
 
In conclusion, this study suggests that platelet transfusions given in standard doses as part of 
a MHP primarily reduce fibrinolysis but do not preserve either platelet aggregation or platelet 
count during bleeding. Platelets administered to bleeding trauma patients appear to have anti-
fibrinolytic effects over and above FFP through inhibition of tPA-mediated fibrinolysis by 
providing an additional dose of PAI-1. Further work in larger cohorts is required to 
ascertain the impact of early platelet delivery during DCR, the role of platelet-derived 
clotting factors on reversing fibrinolysis and potential improvements in outcomes from 
trauma hemorrhage. Whether earlier platelet transfusion has a particular hemostatic benefit in 
all, or selected bleeding patients remains an important question and merits further 





PV, SG, KB and RD designed the study. PV, SG and LSG collected and analyzed data. PV, 
SG, KB, LSG, LG and RD wrote and edited the manuscript. All authors have read and 




1. Cothren CC, Moore EE, Hedegaard HB, Meng K. Epidemiology of urban trauma 
deaths: a comprehensive reassessment 10 years later. World J Surg. 2007;31(7):1507–
11. 
2. Cotton BA, Reddy N, Hatch QM, LeFebvre E, Wade CE, Kozar RA, Gill BS, 
Albarado R, McNutt MK, Holcomb JB. Damage control resuscitation is associated 
with a reduction in resuscitation volumes and improvement in survival in 390 damage 
control laparotomy patients. Ann Surg. 2011, 254(4):598-605. 
3. Holcomb JB, Tilley BC, Baraniuk S, Fox EE, Wade CE, Podbielski JM, del Junco DJ, 
Brasel KJ, Bulger EM, Callcut RA, et al.: Transfusion of plasma, platelets, and red 
blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the 
PROPPR randomized clinical trial. JAMA. 2015;313:471-482. 
4. Chang R, Cardenas JC, Wade CE, Holcomb JB. Advances in the understanding of 
trauma-induced coagulopathy. Blood. 2016 Jul 5 (Epub ahead of print) 
5. Davenport RA, Brohi K. Cause of trauma-induced coagulopathy. Curr Opin 
Anaesthesiol. 2016;29(2):212-9. 
6. Hunt BJ, Allard S, Keeling D, Norfolk D, Stanworth SJ, Pendry K; British Committee 
for Standards in Haematology. A practical guideline for the haematological 
management of major haemorrhage. Br J Haematol. 2015;170(6):788-803. 
 14 
7. National Institute for Health and Care Excellence (UK). Major trauma: assessment 
and initial management. February 17, 2016. 
8. Hoffman M, Monroe DM 3rd. A cell-based model of hemostasis. Thromb Haemost. 
2001;85(6):958-65. 
9. Blair P, Flaumenhaft R. Platelet -granules: Basic biology and clinical correlates. 
Blood Rev. 2009;23(4):177-89. 
10. Brogren H, Karlsson L, Andersson M, Wang L, Erlinge D, Jern S. Platelets synthesize 
large amounts of active plasminogen activator inhibitor 1. Blood. 2004;104(13):3943-
8. 
11. Plow EF, Collen C. The presence and release of 2-antiplasmin from human platelets. 
Blood. 1981;58(6):1069-74. 
12. Moore HB, Moore EE, Gonzalez E, Hansen KC, Dzieciatkowska M, Chapman MP, 
Sauaia A, West B, Banerjee A, Silliman CC. Hemolysis exacerbates 
hyperfibrinolysis, whereas platelolysis shuts down fibrinolysis: evolving concepts of 
the spectrum of fibrinolysis in response to severe injury. Shock 2015;43(1):39-46. 
13. Whyte CS, Swieringa F, Mastenbroek TG, Lionikiene AS, Lancé MD, van der 
Meijden PE, Heemskerk JW, Mutch NJ. Plasminogen associates with 
phosphatidylserine-exposing platelets and contributes to thrombus lysis under 
flow. Blood 2015;125(16):2568-2578 
14. Kutcher ME, Redick BJ, McCreery RC, Crane IM, Greenberg MD, Cachola LM, 
Nelson MF, Cohen MJ. Characterization of platelet dysfunction after trauma. J 
Trauma Acute Care Surg. 2012;73(1):13-19. 
15. Solomon C, Traintinger S, Ziegler B, Hanke A, Rahe-Meyer N, Voelckel W, Schochl 
H. Platelet function following trauma. A multiple electrode aggregometry study. 
Thromb Haemost. 2011;106(2):322-330. 
 15 
16. Windelov NA, Sorensen AM, Perner A, Wanscher M, Larsen CF, Ostrowski SR, 
Johansson PI, Rasmussen LS. Platelet aggregation following trauma: a prospective 
study. Blood Coagul Fibrinolysis. 2014;25(1):67-73. 
17. Khan S, Brohi K, Chana M, Raza I, Stanworth S, Gaarder C, Davenport R; 
International Trauma Research Network (INTRN). Hemostatic resuscitation is neither 
hemostatic nor resuscitative in trauma hemorrhage. J Trauma Acute Care Surg. 
2014;76(3):561-7; discussion 567-8. 
18. Holcomb JB, del Junco DJ, Fox EE, Wade CE, Cohen MJ, Schreiber MA, Alarcon 
LH, Bai Y, Brasel KJ, Bulger EM, et al. The prospective, observational, multicenter, 
major trauma transfusion (PROMMTT) study: comparative effectiveness of a time-
varying treatment with competing risks. JAMA Surg. 2013;148(2):127-36. 
19. Inaba K, Lustenberger T, Rhee P, Holcomb JB, Blackbourne LH, Shulman I, Nelson 
J, Talving P, Demetriades D. The impact of platelet transfusion in massively 
transfused trauma patients. J Am Coll Surg. 2010;211(5):573-9. 
20. Hallet J, Lauzier F, Mailloux O, Trottier V, Archambault P, Zarychanski R, Turgeon 
AF. The use of higher platelet: RBC transfusion ratio in the acute phase of trauma 
resuscitation: a systematic review. Crit Care Med. 2013;41(12):2800-11. 
21. Booth NA, Simpson AJ, Croll A, Bennett B, MacGregor IR. Plasminogen activator 
inhibitor (PAI-1) in plasma and platelets. Br J Haematol. 1988;70(3):327-33. 
22. Sakata Y, Loskutoff DJ, Gladson CL, Hekman CM, Griffin JH. Mechanism of protein 
C-dependent clot lysis: role of plasminogen activator inhibitor. Blood 1986;68(6):1218-
1223. 
23. Brohi K, Cohen MJ, Ganter MT, Matthay MA, Mackersie RC, Pittet JF. Acute 
traumatic coagulopathy: initiated by hypoperfusion: modulated through the protein C 
pathway? Ann Surg 2007, 245:812-818. 
 16 
24. Brohi K, Cohen MJ, Ganter MT, Schultz MJ, Levi M, Mackersie RC, Pittet JF. Acute 
coagulopathy of trauma: hypoperfusion induces systemic anticoagulation and 
hyperfibrinolysis. J Trauma 2008;64(5):1211-1217; discussion 1217. 
25. Nordenhem A, Wiman B. Tissue plasminogen activator (tPA) antigen in plasma: 
correlation with different tPA/inhibitor complexes. Scand J Clin Lab 
Invest. 1998;58(6):475-83. 
26. Collen D, Wiman B. Turnover of antiplasmin, the fast-acting plasmin inhibitor of 
plasma. Blood. 1979;53(2):313-24. 
27. Kim SY, Kim JE, Kim HK, Han KS, Toh CH. Accuracy of platelet counting by 
automated hematologic analyzers in acute leukemia and disseminated intravascular 
coagulation: potential effects of platelet activation. Am J Clin Pathol. 
2010;134(4):634-47. 
28. Cauwenberghs S, Feijge MA, Theunissen E, Heemskerk JW, van Pampus 
EC, Curvers J. Novel methodology for assessment of prophylactic platelet transfusion 
therapy by measuring increased thrombus formation and thrombin generation. Br J 






Figure 1: Flow diagram of patient inclusion and blood sampling. Patients had either 
aggregometry, plasma protein measurement, or both performed at the indicated sampling 
points. PRBC, packed red blood cells.  
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Figure 2: Trends in platelet aggregation during bleeding in patients requiring massive 
transfusion.  A, Adenosine diphosphate (ADP). B, Arachidonic acid (AA). C, Collagen. D, 
thrombin receptor activating peptide (TRAP). Box-whisker plots depict median and interquartile 
range with 10th-90th percentiles. Dashed lines denote normal range. p>0.05 at each time point 
comparing platelets transfused with no platelets transfused (Mann-Whitney U-test). AU, arbitrary 
units. Massive transfusion defined as ≥10 red cell units in 24 hours. 
 
Figure 3: Interval changes in mediators and markers of fibrinolysis during bleeding. A, 
EXTEM maximum lysis (ML). B, Plasminogen Activator Inhibitor-1 (PAI-1). C, tissue 
Plasminogen Activator (tPA). D, Plasmin-antiplasmin complex (PAP). Tukey box plots (A and 
D); * p<0.05, **p<0.01, Wilcoxon matched pairs test. Bars denote mean with 95% confidence 
interval; * p<0.05, ** p<0.01, paired T-test (B and C). n.s., not significant. 
 
Supplemental Figure 1: Trends in platelet aggregation during bleeding in patients requiring 
less than 10 red cell units in 24 hours. A, Adenosine diphosphate (ADP). B, Arachidonic acid 
(AA). C, Collagen. D, thrombin receptor activating peptide (TRAP). Box-whisker plots depict 
median and interquartile range with 10th-90th percentiles. Dashed lines denote normal range. 
p>0.05 at each time point comparing platelets transfused with no platelets transfused (Mann-
Whitney U-test). AU, arbitrary units. 
 
Table 1: Characteristics of the aggregometry cohort. Values in parentheses are 
interquartile range for continuous variables and percentages for categorical variables. P-
values compare platelets transfused vs no platelets transfused (Mann-Whitney U-test or 
Fisher’s exact test). ISS, Injury severity score; AIS, abbreviated injury score; INR, 
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international normalized ratio; PRBC, packed red blood cells; FFP, fresh frozen plasma. ICU, 
intensive care unit. 
 
 
Table 2: Characteristics of patients with samples during bleeding. Patients were divided 
into two groups based on whether or not platelets were transfused prior to the sample being 
taken. Values are median with interquartile range unless stated. P-values compare platelets 
transfused vs no platelets transfused at each sampling time point (Mann-Whitney U-test). 
1Values are n (%). 
 
Table 3: Interval changes in viscoelastic variables and plasma proteins during four-
PRBC intervals. Values are mean with 95% confidence intervals and compared with one-
way ANOVA unless specified. *p<0.05, RBC+FFP+platelets vs RBC+FFP, one-way 
ANOVA with Tukey’s multiple comparisons test. 1EXTEM value unless specified 2Values 









Hemorrhage is the principal cause of preventable death due to injury.1 Contemporary 
damage-control resuscitation (DCR) is characterised by expedited hemorrhage control with 
simultaneous and empiric transfusion of blood and blood products in high ratios.2  
Maintaining hemostatic potential through early administration of plasma and platelets in high 
volumes alongside transfusion of packed red blood cells (PRBCs) minimises dilutional 
coagulopathy and is associated with improved outcomes.3  However, the effects of platelet 
transfusions remain unclear, while the provision of platelet transfusions can be challenging.  
Platelet function is known to be reduced in Trauma-Induced Coagulopathy (TIC),4,5 but the 
effects of platelet transfusion on coagulation during active bleeding are unknown. This 
knowledge gap has been highlighted by several contemporary major hemorrhage 
guidelines.6,7  
 
Platelets promote coagulation primarily by adhering to the endothelium or subendothelium to 
form aggregates at sites of vascular injury, and by providing a phospholipid platform to 
support thrombin generation.8 Haemostasis is further amplified through the release of 
reactive mediators from platelet storage granules into the plasma space,9 including clotting 
factors and mediators of fibrinolysis. In particular, platelets contain a large pool of 
plasminogen activator inhibitor-1 (PAI-1)10 and alpha -2 antiplasmin (A2AP),11 which are 
hypothesised to represent an important mechanism through which platelets attenuate tissue 




































































is common after severe injury and associated with increased mortality, although the 
mechanisms of this remain unknown.14-16 Attempts to support platelet function through 
transfusion of allogeneic platelets during major haemorrhage therefore seems logical, but to 
date no studies have evaluated how platelet transfusions affect hemostasis during bleeding in 
trauma patients. 
 
Our working hypothesis was that platelet transfusions exert their effects either through 
augmenting aggregation, promoting thrombin generation or by the release of granule contents 
into the plasma space. In this study, our objectives were to describe changes in whole blood 
platelet aggregation, rotational thromboelastometry, circulating levels of platelet-derived 
clotting factors, and plasma markers of fibrinolysis resulting from platelet transfusion. We 
compared interval changes in bleeding trauma patients receiving blood component therapy 




Study design and participants 
Patients recruited into the ACIT II (UK CRN ID 5637) prospective, observational study at an 
urban major trauma centre in the United Kingdom between January 2008 and November 
2015 were eligible for inclusion. Entry and exclusion criteria for ACIT II have been 
published in detail previously.17 The study was approved by the local Research Ethics 
Committee (reference 07/Q0603/29). For this study patients who received less than 4 units of 
packed red blood cells (PRBCs) were retrospectively excluded, to focus on bleeding patients 



































































for patient recruitment was initially provided by an independent physician, with written 
informed consent obtained from a patient or relative as soon as possible after enrollment. 
 
Major Hemorrhage Protocol 
At our institution, activation criteria for the MHP are a systolic blood pressure <90mmHg, 
poor response to initial fluid resuscitation and/or clinical suspicion of active hemorrhage.  
MHP activation occurs either from scene by the physician-led prehospital care team or upon 
arrival in the Emergency Department (ED) by the trauma team leader. Empiric transfusion 
with a FFP:Platelet:PRBC target ratio of 1:1:1 is initiated with ‘pack A’, which contains 4 
units of PRBCs and 4 units of FFP. Universal donor PRBCs and thawed FFP are available in 
ED for immediate transfusion. If bleeding continues, ‘pack B’ and all subsequent packs 
provide 6 PRBC, 6 FFP, 2 pools of cryoprecipitate and 1 apheresis unit of platelets; the order 
of administration of these products is at the discretion of the clinical team. The MHP was 
updated to include tranexamic acid (TXA) administration in February 2011 and pre-hospital 
transfusion of up to four units of PRBCs in January 2014.  
 
Blood sampling  
Blood was drawn for research purposes within 20 minutes of arrival in ED from either the 
femoral vein or antecubital fossa, alongside routine laboratory tests. Blood product use prior 
to this initial sample draw was recorded. Platelet counts were measured with a Coulter 
LH750 hematology analyzer (Beckman Coulter, CA, USA; normal range 150-400x109/L). 
Point-of-care arterial blood gas analysis was performed to determine base deficit (BD) and 
lactate concentration. In patients who received transfusion of blood products, further samples 
were obtained after every 4th unit of PRBC, up to and including the 12th unit. Samples were 




































































Platelet Aggregation and Thromboelastometry 
Platelet aggregation was assayed in whole blood with multiple electrode impedance 
aggregometry using the Multiplate analyzer (Roche pharmaceuticals, Sussex, UK). 
Samples were processed according to the manufacturer’s instructions. Briefly, blood was 
collected into a 3ml vacutainer (Roche pharmaceuticals) containing >15g/ml hirudin. 
Aggregation was measured in 300l of blood over six minutes in response to 6.5M 
adenosine diphosphate (ADP), 0.5mM Arachidonic acid (AA), 3.2g/ml collagen and 32M 
thrombin-receptor activating peptide-6 (TRAP; final concentrations given). Results are 
reported as area under the curve (AUC) in arbitrary units. Hypo- and hyperfunction were 
defined according to references ranges stated by the manufacturer (570-1130U for ADP, 710-
1150U for AA, 720-1250U for collagen and 840-1280U for TRAP). Rotational 
thromboelastometry (ROTEM) was performed on citrated whole blood using a ROTEM 
delta instrument in the presence of tissue factor (EXTEM) and with the addition of 
cytochalasin D, an inhibitor of platelet aggregation (FIBTEM).  
 
Clotting Factors and Fibrinolytic markers 
For quantification of plasma coagulation protein levels, blood was drawn into 4.5ml glass 
vacutainer containing 3.2% sodium citrate (Becton, Dickinson and Company, Plymouth, UK) 
and centrifuged at 1,750g for ten minutes. The plasma component was then removed and re-
centrifuged at the same speed and duration prior to storage at -80C. Immediately after 
thawing levels of factor II (reference range 70-146iu/dL), factor V (66-114iu/dL), factor XIII 
(55-158iu/dL), D-dimer (0-440ng/mL), von Willebrand antigen (50-160iu/dL), soluble fibrin 
monomer complex (0-6g/mL) and alpha-2 antiplasmin (A2AP; 68-136iu/dL) were 



































































UK) according to standard protocols; results are reported in international units. Levels of 
PAI-1 (4-43ng/mL), tPA (2-12ng/mL), plasmin-antiplasmin complex (PAP; 120-700g/L) 
and prothrombin fragments 1+2 (PF1+2; 69-229pmol/L) were measured using sandwich 
enzyme-linked immunosorbent assay (ELISA; Asserchrom®, Diagnostica Stago). 
 
Data Collection  
Demographic data, injury characteristics and physiological variables were collected 
prospectively. Cessation of blood product transfusion was used as a surrogate of hemostasis 
for the purposes of this study. Daily follow-up was performed for the first 28 days of hospital 
stay or until death or discharge.  Multiple Organ Dysfunction Syndrome (MODS) was 




Data were analysed separately to assess the effect of platelet transfusion on platelet 
aggregation, with a subgroup analysis to examine the changes in coagulation factors and 
ROTEM.  First, to study the impact of platelet transfusion on platelet aggregation over time 
during resuscitation, patients were divided into two groups at each sampling point (4 unit 
PRBC, 8 unit PRBC, 12 unit PRBC): (1) those that received a platelet transfusion and (2) 
those that did not receive a platelet transfusion prior to each sampling point. To mitigate the 
potential effects of selection bias, we divided patients into those who received a massive 
transfusion (MT, defined as ≥ 10 PRBC units in 24 hours) and patients who required less than 
10 PRBC units. Second, we divided all available 4 unit PRBC intervals into three groups 
depending on the blood products administered during this interval: PRBCs only; PRBCs and 



































































transfusion on plasma protein levels and viscoelastic measurements from those of FFP. 
Interval changes were calculated by subtracting the value at the end of the interval from the 
value at the beginning of the interval.  
 
Data analysis was performed using Excel v15.2 (Microsoft, CA) and Prism v6.0 (GraphPad 
software, CA). Normal-quantile plots were used to assess the distribution of continuous data. 
Data from non-parametric distributions are reported as median with interquartile range (IQR) 
and were compared with the Mann-Whitney U-test, Kruskall-Wallis test with Dunn’s post-
test, or Wilcoxon matched pairs test. Data from parametric distributions are presented as 
mean +/- 95% confidence intervals and were compared with Student’s or paired T-test as 
applicable, or one-way analysis of variance (ANOVA) with Tukey’s post-hoc test for 
multiple comparisons. Correlation was assessed with Spearman’s coefficient. Categorical 
data are displayed as number and percentage and were compared with Fisher’s exact test. A 




One-hundred sixty-one patients received at least 4 PRBCs and were included in the study 
(figure 1). Eighty-two patients received PRBC transfusion prior to baseline sampling, median 
1 PRBC units (0-2).  Patients who received platelets (n=107) during the first 24 hours had 
similar injury severity to those who did not receive a platelet transfusion (n=54) but were 
significantly more shocked, with longer length of hospital stay and increased rates of organ 
failure (Table 1).  A non-significant trend towards reduced mortality at 24 hours in patients 
receiving platelets was observed (platelets transfused: 8/107 (7%) vs no platelets transfused 



































































minutes and patients who required a platelet transfusion received significantly more blood 
and blood products (FFP, cryoprecipitate) during the first 24 hours (Table 1).  The average 
ratio of platelets to PRBCs, assuming one apheresis unit to be equivalent to 6 units of 
PRBCs, was 0.3 between 0-4 PRBCs, 0.9 between 5-8 PRBCs and 1.2 between 9-12 PRBCs. 
 
On admission to ED, more than one in four patients who required over 4 PRBC units had 
evidence of reduced platelet aggregation in response to agonist stimulation: ADP: 70 (42%), 
AA: 59 (36%), collagen: 38 (24%), TRAP: 38 (24%). Patients who received ≥10PRBCs, 
(n=42) had lower platelet aggregation at admission compared to patients who received 4-9 
PRBC units: ADP, MT 477 (158-790) vs no MT 681 (331-1007), p=0.016; AA, MT 635 
(411-893) vs no MT 891 (591-1242), p=0.001; collagen, MT 747 (4678-993) vs no MT 940 
(559-1262), p=0.033; TRAP, MT 1032 (650-1171) vs no MT 1277 (903-1584), p=0.006. 
Seventy-one patients had at least one additional sample taken for aggregometry during 
bleeding, after an average of 57 minutes (4 PRBC interval), 87 minutes (8 PRBC interval) 
and 130 minutes (12 PRBC interval) from admission. Compared to patients who only 
underwent baseline sampling, these patients had a similar severity of injury (30 (22-38) vs 
(29 (18-40), p=0.10), depth of shock (8.9 (6.0-16.9) vs 7.4 (3.9-13mmol/L), p=0.13), and 
overall mortality (20/71 (28%) vs 23/90 (26%), p=0.72) 
 
In patients who received a massive transfusion and had samples during hemorrhage, platelet 
aggregation declined significantly during resuscitation (figure 2A-D) compared with 
admission. A similar pattern in aggregation was observed in patients who received more than 
four PRBC units but did not require a massive transfusion (supplemental figure 1A-D). 



































































prior to each sampling point, levels of platelet aggregation were similar (p>0.05 at each 
sample time-point). At each sampling point, groups were comparable in terms of injury 
severity and depth of shock, although patients who received platelets tended to have samples 
taken later after admission (table 2). Aggregation in response to each of the agonists 
deteriorated at each sampling point during bleeding compared to baseline, and on average by 
8 PRBC units had decreased from the admission value by 81% in patients who did not 
receive platelets and 78% in patients who had a platelet transfusion. Platelet count also 
declined during haemorrhage irrespective of platelet transfusion. After 8 PRBC units, the 
platelet count in those who received platelets was 97 (71-106) x109/L versus 109 (79-137) 
x109/L (p=0.81) in those who did not receive a platelet transfusion by this sample point.  
 
We next assessed the efficacy of platelet transfusion on ROTEM variables in a subset of 
patients who had plasma coagulation protein levels measured during bleeding at each 4 unit 
PRBC interval (n=89).  Overall, 115 interval samples were available for analysis - FFP was 
administered in 85 intervals of which 29 included at least one pool of platelets (Table 2).  
Compared to the main study cohort, this subgroup were more severely injured (ISS 34 [25-
42] vs 29 [20-38], p=0.03) but had a similar degree of shock (BD 8.9 +/- 1.3mmol/L vs 9.8 
+/- 1.1mmol/L, p=0.31), PRBC transfusion (8 [6-11] units vs 7 [5-10] units, p=0.09) and 28-
day mortality (29 [33%] vs 40 [28%], p=0.24). The proportion of patients who received TXA 
prior to or during the interval was similar when PRBCs were given alone (33%), with FFP 
(38%) or with FFP and platelets (50%; p=0.39, chi-squared test). Intervals which contained 
platelets and FFP were longer in duration compared to those containing FFP without platelets 




































































Comparing intervals in which platelets were transfused with those in which only FFP and 
PRBC were administered, there was no significant difference in viscoelastic measurement of 
clotting time, clot formation or clot strength (Table 3).  However, platelet transfusion was 
associated with a significant reduction in EXTEM maximum lysis (ML) (Table 3 and Figure 
3A).  Changes in circulating clotting factor levels were similar, irrespective of whether or not 
platelet transfusions were administered during a 4 unit PRBC interval (Table 3). Platelet 
transfusion during an interval was associated with a significant increase in circulating levels 
of PAI-1 compared to intervals in which PRBCs and FFP were administered (Figure 3B). 
Conversely, levels of soluble tPA decreased in intervals where platelets were transfused in 
combination with PRBCs and FFP (Figure 3C). PAP complex levels declined in intervals 
containing PRBCs and FFP regardless of whether platelets were transfused (Figure 3D). No 
correlation was observed between interval duration and change in EXTEM ML (r=0.13, 
p=0.27), PAI-1 (r=0.17, p= 0.19) or tPA (r=-0.07, p=0.63). Overall, the only clear effects of 
platelet transfusions appeared to be a reduction in fibrinolysis with minimal effect on other 




In this prospective single-centre cohort study, the strongest effect of platelet transfusion 
during trauma hemorrhage appears to be reduction of fibrinolysis without improvement in 
clot strength or clotting times.  Administering platelets as part of a major haemorrhage 
protocol did not restore platelet aggregation or platelet count. Compared to transfusion of 
FFP and PRBC alone, platelets transfusions improved viscoelastic measures of fibrinolysis 
with increased plasma PAI-1 levels and reduced circulating tPA. In cohort studies, high 



































































early deaths due to exsanguination in the 1:1:1 arm of the PROPPR randomized control trial 
may due to the effects of early platelet administration rather than (or as well as) the higher 
doses of blood components. Reduction of hyperfibrinolysis] may be a key mechanism by 
which early platelet transfusion improves hemostasis in TIC.  
 
Platelets contain a broad array of pro- and anti-coagulant factors which are released into the 
plasma space upon activation.9 Of particular relevance to the potential role of platelets in 
Acute Traumatic Coagulopathy (ATC) and TIC are inhibitors of fibrinolysis including PAI-1. 
Although the activity of platelet-derived PAI-1 has been questioned,21 recent evidence 
suggests that the active form is stored in large quantities within platelet alpha granules.10 In 
ATC, activated protein C-dependent fibrinolysis is thought to occur through inhibition of 
PAI-1, which allows tPA mediated plasminogen cleavage to proceed unchecked.22-24 Our 
findings suggest that transfusion of stored platelets may provide an important source of PAI-
1, which forms an inactive complex with circulating tPA and hypothetically reduces the level 
of free tPA detectable in plasma.25 FFP contains antiplasmin although platelet transfusion had 
an additive effect on reversal of functional fibrinolysis as demonstrated by a reduced 
maximum lysis. Although changes in PAP and D-dimer levels were not significantly different 
after platelet transfusions, this may be attributable to the long half-life of these biomarkers in 
the circulation. Both assays describe prior fibrinolytic activation rather than the dynamic 
changes in fibrinolysis during bleeding.26 This apparent predominant effect of platelet 
transfusion is supported by in vitro evidence that platelet lysate attenuates tPA-dependent 
fibrinolysis12 and raises the question of whether earlier administration of platelets could 




































































Trauma-induced platelet dysfunction on arrival to ED has been previously described by 
several authors,14-16 and it is plausible that the conditions which impair the function of 
endogenous platelets may have the same effect on stored platelets administered in 
transfusion. Whether trauma-induced platelet dysfunction is an intrinsic platelet defect or the 
result of circulating conditions is unknown and requires further study. With regards to 
platelet count, it is possible that the rate of platelet loss through ongoing bleeding exceeded 
the number of platelets being administered in our patient cohort. Alternatively, stored 
platelets may form microaggregates or be recruited to thrombus formation, and thus escape 
detection by the laboratory platelet count.27 These hypotheses remain speculative however, 
and further investigation is required to determine how the post-injury intravascular milieu 
impacts upon the function of both stored and endogenous platelets. 
 
There are a number of limitations to this study, principally as a result of its observational 
design. First, comparisons of interval changes in clotting factor levels and viscoelastic tests 
could in theory be influenced by variations in the rate of blood loss and the time of sampling, 
which was slightly later after admission in patients receiving platelets. Second, given the 
sample sizes for each interval we were unable to fully control for concomitant administration 
of FFP and cryoprecipitate. Third, we were not able to evaluate the effect of timing of platelet 
transfusion as part of our MHP. In particular, whether ‘up front’ platelet transfusion, as 
administered in the 1:1:1 arm of the PROPPR trial, conferred additional hemostatic benefits 
could not be addressed in this study due to the design of the MHP at out institution.  Platelets 
are delivered in the second MHP pack and therefore later in the clinical episode. Further 
work is required to assess other possible sources for the delayed rise in PAI-1 e.g. reperfusion 
injury of hypoperfused endothelium.  Fourth, we did not directly measure thrombin 



































































has been advocated as a method to support thrombin generation28 although we found no 
significant difference in PF 1+2 fragments between groups. Fifth, we did not perform any 
functional coagulation tests on the apheresis platelet units themselves as this forms part of an 
ongoing study. Finally, we did not undertake a detailed evaluation of the impact of platelet 
transfusion on clinical outcomes although these have previously been described in larger 
multi-centre studies.3,18 Our novel findings demonstrating a potential role for platelets in 
reducing fibrinolytic activity as measured by laboratory assays, and requires clinical 
validation in larger trauma trials.  
 
In conclusion, this study suggests that platelet transfusions given in standard doses as part of 
a MHP primarily reduce fibrinolysis but do not preserve either platelet aggregation or platelet 
count during bleeding. Platelets administered to bleeding trauma patients appear to have anti-
fibrinolytic effects over and above FFP through inhibition of tPA-mediated fibrinolysis by 
providing an additional dose of PAI-1. Further work in larger cohorts is required to ascertain 
the impact of early platelet delivery during DCR, the role of platelet-derived clotting factors 
on reversing fibrinolysis and potential improvements in outcomes from trauma hemorrhage. 
Whether earlier platelet transfusion has a particular hemostatic benefit in all, or selected 
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Figure 1: Flow diagram of patient inclusion and blood sampling. Patients had either 
aggregometry, plasma protein measurement, or both performed at the indicated sampling points. 
PRBC, packed red blood cells. 
 
Figure 2: Trends in platelet aggregation during bleeding in patients requiring massive 
transfusion.  A, Adenosine diphosphate (ADP). B, Arachidonic acid (AA). C, Collagen. D, 



































































range with 10th-90th percentiles. Dashed lines denote normal range. p>0.05 at each time point 
comparing platelets transfused with no platelets transfused (Mann-Whitney U-test). AU, arbitrary 
units. Massive transfusion defined as ≥10 red cell units in 24 hours. 
 
Figure 3: Interval changes in mediators and markers of fibrinolysis during bleeding. A, 
EXTEM maximum lysis (ML). B, Plasminogen Activator Inhibitor-1 (PAI-1). C, tissue 
Plasminogen Activator (tPA). D, Plasmin-antiplasmin complex (PAP). Tukey box plots (A and 
D); * p<0.05, **p<0.01, Wilcoxon matched pairs test. Bars denote mean with 95% confidence 
interval; * p<0.05, ** p<0.01, paired T-test (B and C). n.s., not significant. 
 
Supplemental Figure 1: Trends in platelet aggregation during bleeding in patients requiring 
less than 10 red cell units in 24 hours. A, Adenosine diphosphate (ADP). B, Arachidonic acid 
(AA). C, Collagen. D, thrombin receptor activating peptide (TRAP). Box-whisker plots depict 
median and interquartile range with 10th-90th percentiles. Dashed lines denote normal range. 
p>0.05 at each time point comparing platelets transfused with no platelets transfused (Mann-
Whitney U-test). AU, arbitrary units. 
 
Table 1: Characteristics of the aggregometry cohort. Values in parentheses are 
interquartile range for continuous variables and percentages for categorical variables. P-
values compare platelets transfused vs no platelets transfused (Mann-Whitney U-test or 
Fisher’s exact test). ISS, Injury severity score; AIS, abbreviated injury score; INR, 
international normalized ratio; PRBC, packed red blood cells; FFP, fresh frozen plasma. ICU, 





































































Table 2: Characteristics of patients with samples during bleeding. Patients were divided 
into two groups based on whether or not platelets were transfused prior to the sample being 
taken. Values are median with interquartile range unless stated. P-values compare platelets 
transfused vs no platelets transfused at each sampling time point (Mann-Whitney U-test). 
1Values are n (%). 
 
Table 3: Interval changes in viscoelastic variables and plasma proteins during four-
PRBC intervals. Values are mean with 95% confidence intervals and compared with one-
way ANOVA unless specified. *p<0.05, RBC+FFP+platelets vs RBC+FFP, one-way 
ANOVA with Tukey’s multiple comparisons test. 1EXTEM value unless specified 2Values 




































































Table 1: Characteristics of the study cohort. 









Patient characteristics     
Male gender 112 (70) 73 (68) 39 (72) 0.72 
Age, years 37 (24-57) 33 (24-51) 42 (28-59) 0.04 
Injury Severity Score 29 (20-38) 29 (20-41) 29 (17-38) 0.68 
ISS>15 138 (86)  95 (89) 43 (80) 0.04 
Base Deficit, mmol/L  7.9 (4.0-15.1) 9.0 (5.1-16.5) 6.0 (2.7-9.6) 0.006 
Blunt Mechanism 120 (75) 30 (28) 11 (20) 0.34 
AIS Head ≥3 54 (34) 36 (34) 18 (33) 1.0 
Baseline Laboratory results     
INR>1.2 71 (44) 53 (50) 18 (33) 0.06 
EXTEM CA5≤37mm 64 (40) 45 (42) 19 (35) 0.50 
Fluids prior to baseline sampling      
Crystalloid, ml 250 (0-600) 200 (0-735) 400 (0-500) 0.45 
Packed red blood cells, units 0 (0-2) 1 (0-2) 0 (0-2) 0.31 
Tranexamic acid 83 (52) 60 (56) 23 (43) 0.13 
Fluids at 24 hours      
Crystalloid, ml 3575 (2225-5050) 3700 (2455-5200) 3200 (2000-5000) 0.11 
Colloid, ml 0 (0-1500) 250 (0-1750) 0 (0-1000) 0.18 
PRBC, units 7 (5-10) 8 (6-11) 5 (4-6) <0.001 
FFP, units 5 (4-8) 7 (4-10) 4 (0-4) <0.001 
Cryoprecipitate, pools 2 (0-2) 2 (2-3) 0 (0-0) <0.001 
Platelets, apheresis units 1 (0-2) 1 (1-2) 0 (0-0) <0.001 
≥10 PRBC units 42 (26) 38 (36) 4 (7) <0.001 
Outcome     
Length of stay, days1 30 (14-50) 33 (16-56) 24 (13-39) 0.02 
ICU length of stay, days1 6 (1-16) 8 (2-18) 3 (0-12) 0.03 
Infection 84 (52) 61 (56) 31 (54) 1.0 
MODS 114 (71) 85 (79) 29 (53) <0.001 
24-hour mortality 17 (11) 8 (7) 9 (17) 0.10 
  28-day mortality 40 (25) 25 (23) 15 (28) 0.56 
Values in parentheses are interquartile range for continuous variables and percentages for categorical 
variables. Injury Severity Score (ISS); AIS, Abbreviated Injury Score; INR, International Normalized 
Ratio; PRBCs, Packed Red Blood Cells; FFP, Fresh Frozen Plasma; ICU, Intensive Care Unit; 
MODS, Multiple Organ Dysfunction Syndrome.  Comparison between platelets transfused vs no 
platelets transfused (Mann-Whitney U-test or Fisher’s exact test). 1Survivors only. 
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Table 2: Characteristics of patients with samples during bleeding. 
 
 
Patients were divided into two groups at each sampling point based on whether or not platelets were transfused prior to the sample being taken. Values are 
median with interquartile range unless stated. P-values compare platelets vs no platelets at each sampling point (Mann-Whitney U-test).  ISS, Injury Severity 
Score. PRBCs, packed red blood cells. 1Values are n (%)
 4PRBC 8PRBC 12PRBC 



















ISS 34 (25-42) 27 (20-36) 0.259 36 (29-41) 27 (25-38) 0.273 34 (16-50) 29 (26-48) 0.99 
Base Deficit, mmol/L 8.3 (5.1-15.0) 7.5 (5.5-10.9) 0.642 9.2 (4.7-17.2) 9.2 (6.2-15.3) 0.946 10.0 (8.9-10.6) 15.1 (8.0-21.0) 0.296 
Time from admission to 
sample, minutes 
57 (36-81) 70 (51-144) 0.148 63 (53-147) 115 (77-223) 0.051 48 (45-89) 131 (98-207) 0.014 
PRBCs in 24 hours, units 7 (4-9) 8 (6-11) 0.536 12 (8-18) 10 (8-16) 0.596 19 (15-25) 16 (12-25) 0.686 
Mortality1 29 (33) 5 (26) 0.787 9 (53) 7 (35) 0.331 1 (33) 8 (53) 1.00 





RBC + FFP 
(n=56) 






    
Clotting Time, seconds 15 (3-28) -1 (-10 – 7) -14 (-33 – 5) 0.014 
Clot Formation Time, seconds 59 (20-98) 17 (-4 – 37) -4 (-50 – 42) 0.039 
Clot Amplitude at 5 minutes, mm -7 (-11 – -4)  -4 (-6 – -2) -2 (-7 – 3) 0.102 
Maximum Clot Firmness, mm -6 (-10 – -3) -1 (-4 – 2) -1 (-6 – 4) 0.085 
EXTEM-FIBTEM Maximum Clot 
Firmness, mm 
-2 (-7 – 3) -1 (-4 – 2) -3 (-8 – 2)  0.743 
Maximum Lysis, %2 -1 (-2 – 2) -1 (-2 – 2)  -3 (-7 – 0)* 0.044 
 
Coagulation factors 
    
Factor II, IU/dL -11 (-19 – -2) -4 (-9 – 1) -3 (-9 – 2)   0.246 
Factor V, IU/dL -9 (-18 – -1)  -1 (-7 – 4) -3 (-10 – 4) 0.239 
Factor XIII, IU/dL -13 (-20 – -6) 5 (-2 – 12) 8 (-3 – 19) 0.002 
Von Willebrand Antigen, IU/dL -64 (-94 – -35) -49 (-72 – -25) -47 (-92 – -2)  0.725 
 
Thrombin generation and clot formation 
    
Prothrombin fragments 1+2, nmol/L -3 (-5 – -1)   -2 (-3 – 0) -1 (-4 – 2) 0.313 
Soluble fibrin monomer complex2, g/L 10 (-34 – 44) -31 (-70 – 7) -13 (-76 – 37) 0.158 
 
Mediators and markers of fibrinolysis 
    
Antithrombin, IU/dL -12 (-21 – -3) 0 (-6 – 5) -4 (-14 – 6) 0.082 
Plasimnogen-activator inhibitor-1, ng/ml 12 (2 – 23)  10 (-2 – 23) 31 (11-50)* 0.022 
Tissue plasminogen activator, ng/mL 6 (1 – 12) 0 (-3 – 4)  -7 (-16 – 2)
 
0.013 
Alpha-2 antiplasmin -12 (-24 – 0) 0 (-10 – 8)  2 (-12 – 17)  0.207 







Plasmin-antiplasmin complex2, g/L -3719 (-6654 – 
-784) 
-2631 (-4460 –      
-802)  
-3680 (-5820 –      
-1539) 
0.737 
Values are mean with 95% confidence intervals and compared with one-way ANOVA unless specified. *p<0.05, 
RBC+FFP+platelets vs RBC+FFP, one-way ANOVA with Tukey’s multiple comparisons test. 1EXTEM value 
unless specified 2Values are median with interquartile range. p-values derived from Kruskal-Wallis test with 
Dunn’s post-test correction. 
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